Tissue Bioprinting Articles & Analysis
18 news found
This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug discovery, cancer research, and tissue engineering. ...
ByCELLINK
3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human ...
About Prellis Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. ...
Recent research in the field of tissue engineering and bioprinting has led to extremely promising results, paving the way for new therapeutic strategies for tissue repair and/or substitution as well as for personalized medicine. ...
ByPoietis
Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its ...
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its ...
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary ...
The next level of 3D cell culture presents organ-on-a-chip models or 3D bio-printed tissues, which can be used to model human organs on a miniature scale. ...
ByUPM
” Atelerix’s range of innovative products, including BeadReady™ (used for cells in suspension), WellReady™ (used for plated cells and cell-laden bioprinted constructs) and TissueReady™ (used for tissue samples and larger cell-laden bioprinted constructs), will be available for purchase from CELLINK, so that the ...
“This is such an exciting time for BIOLIFE4D, and I’m thrilled to accept the challenge of leading the Company into its first growth stage, toward commercialization of our pioneering 3D bioprinting technologies,” said Lewis. “From treatments like valve replacement and cardiac patches, to full-on heart transplants, to clinical research and testing – ...
About Poietis : Bioprinting company specializing in the development of new biomanufacturing solutions, based on Laser-Assisted Bioprinting, for human tissues. Poietis mission is to provide clinicians and patients with tissue engineering therapies thanks to its innovative, proprietary Next-Generation ...
ByPoietis
Poietis has developed the multimodal NGB (« Next Generation Bioprinting ») bioprinting platform declined in two versions: one for in vitro tissue engineering research (NGB-R) and a clinical version (NGB-C) for the production of implantable bioprinted tissues. ...
ByPoietis
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. ...
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint a mini human heart, a significant step toward its goal of producing a full-sized human heart viable for transplant. ...
About Poietis : Poietis is a biotechnology company specialized in the development and the manufacturing of human tissues using 4D bioprinting. Since its inception in 2014, the company has been developing different physiological models, particularly in partnership with the world’s leading pharmaceutical and cosmetic groups. Poietis markets Poieskin®, the ...
ByPoietis
Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded Bellicum Pharmaceuticals, a NASDAQ-traded cellular immunotherapy company. 3DBio Therapeutics is advancing therapeutic-grade bioprinting to manufacture living tissues designed and created specifically for each individual patient. ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. ...
ByPoietis
Poietis, leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. ...
ByPoietis